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Introduction
Luteal phase deficiency is a common feature of cycles
resulting from stimulation of follicular development, in
cycles downregulated with gonadotropin-releasing hor-
mone (GnRH) agonist as well as those using a GnRH
antagonist [1,2]. It is characterized by premature regres-
sion of the corpus luteum, leading to a shortened luteal
phase of less than 10 days, low progesterone levels, and
delayed secretory transformation of the endometrium
[3]. The consequences of luteal phase deficiency are a
reduced embryo implantation rate, a lower pregnancy
rate, and an increased miscarriage rate when pregnancy
is established; thus, luteal phase support is a common
practice in assisted reproductive technology (ART) to
significantly improve embryo implantation, clinical
pregnancy rate, and delivery rate [2]. The therapeutic
regimens routinely used for supporting the luteal phase
are intramuscular human chorionic gonadotropin (hCG)
or vaginal progesterone with or without estrogen. hCG
administration is associated with increased risk of
ovarian hyperstimulation syndrome (OHSS), and pro-
gesterone is the preferred choice [4]. Recently, the ben-
eficial effect of GnRH agonist for luteal phase support
has been suggested in some studies [5–7]. The mecha-
nism of the presumed beneficial effect of luteal phase
agonist administration is poorly defined. It was hypoth-
esized that GnRH agonist may support the corpus lu-
teum by stimulating the secretion of luteinizing hormone
by pituitary gonadotroph cells, or by acting directly on
the endometrium through the locally expressed recep-
tors [8]. Tesarik et al reported a direct effect of GnRH
agonist on the embryo in oocyte donors [5]. The aim of
this study was to assess the effect of single dose GnRH
BENEFICIAL EFFECT OF LUTEAL-PHASE
GONADOTROPIN-RELEASING HORMONE AGONIST
ADMINISTRATION ON IMPLANTATION RATE AFTER
INTRACYTOPLASMIC SPERM INJECTION
Dehghani Firouzabadi Razieh, Ayazi Rozbahani Maryam*, Tabibnejad Nasim
Research and Clinical Center for Infertility, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
SUMMARY
Objective: To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal
phase, on intracytoplasmic sperm injection (ICSI) outcome.
Materials and Methods: One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled
in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation
rate and clinical pregnancy rate were the main outcomes.
Results: Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a signif-
icant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as com-
pared with placebo.
Conclusion: Luteal phase GnRH agonist administration enhances ICSI clinical outcomes. [Taiwan J Obstet Gynecol
2009;48(3):245–248]
Key Words: embryo implantation, GnRH agonist, intracytoplasmic sperm injection, luteal phase support
*Correspondence to: Dr Ayazi Rozbahani Maryam,
Research and Clinical Center for Infertility, Bouali
Ave, Safaieyeh, Yazd 8916877391, Iran.
E-mail: ayaziroz@yahoo.com
Accepted: July 3, 2008
agonist administration, as luteal phase support, on
intracytoplasmic sperm injection (ICSI) outcome.
Materials and Methods
Patients
In order to study the effect of GnRH agonist adminis-
tration on pregnancy outcome, a total of 180 women
who were candidates for ICSI, and who were referred to
the Research and Clinical Center for Infertility in Yazd,
were screened. Patients older than 40 years old and
poor responders in previous cycles (defined as day 3
follicle-stimulating hormone > 10 IU/mL or less than
four follicles at the time of hCG injection in the previ-
ous cycle) were excluded from the study. The patients
were randomly divided into two groups: an experimen-
tal group (n = 90) and a control group (n = 90). Random
selection to either group was performed by drawing a
piece of paper from a bag containing equal numbers of
papers assigned to each group.
The baseline characteristics of the two groups, espe-
cially age, duration of infertility, duration and dosage
of hormonal stimulation, number of retrieved oocytes
and transferred embryos, were not statistically different
(Table 1).
Written informed consent was given by the patients
in the case group. This prospective study has been ap-
proved by the ethics committee of the Research and
Clinical Center for Infertility, Yazd University of Medical
Sciences.
Ovarian stimulation protocol
For pituitary downregulation and endogenous gonad-
otropin depletion, patients in both groups were treated
by daily injection of subcutaneous buserelin 500 μg
(Suprefact; Aventis, Frankfurt, Germany) from day 21
of the menstrual cycle, followed by 250 μg daily from
the first day of vaginal bleeding. Follicular stimulation
was initiated from day 2 of the menstrual cycle with
daily use of recombinant follicle-stimulating hormone
150–225 IU (Gonal-F; Serono, Aubonne, Switzerland)
and was continued until at least two follicles with diam-
eter ≥18 mm were observed by vaginal ultrasonography.
Oocyte maturation was induced by 10,000 IU of hCG
intramuscularly (Pregnyl; Organon, Cambridge, UK).
Oocyte retrieval was performed 34–36 hours after
hCG administration by a 17-gauge needle (Cook,
Queensland, Australia) under vaginal ultrasound guid-
ance. Two or three embryos were transferred within
48–72 hours by a Labotect catheter (Labotect GmbH,
Gottingen, Germany). The luteal phase was supported
by administration of progesterone 800 mg (Cyclogest;
Alpharma, Barnstaple, UK) daily and was continued to
week 11 of pregnancy. In the study group, women were
given a single dose of triptorelin 0.1 mg (Decapeptyl;
Ipsen Pharma, Barcelona, Spain) subcutaneously on day
3 after embryo transfer. The controls received placebo
at the same time. Chemical pregnancy was determined
by measuring serum β-hCG level 14 days after embryo
transfer. Clinical pregnancy was defined as the pres-
ence of an intrauterine gestational sac with embryonic
cardiac activity observed by vaginal ultrasound.
Statistical analysis
The SPSS 15.0 software (SPSS Inc., Chicago, IL, USA)
was used to analyze data of all patients. The baseline
characteristics of the two groups of patients were com-
pared by the Mann-Whitney U test. Differences in the
pregnancy outcome in the study and control group were
analyzed using the χ2 test. The implantation rate was
calculated as the ratio of the number of embryonic sacs
detected by sonography to the total number of embryos
transferred. The rate of clinical pregnancy was expressed
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Table 1. Basic demographic and ovarian stimulation cycle characteristics of the gonadotropin-releasing hormone (GnRH) 
agonist treatment group and placebo group*
Characteristics
Patient groups†
Luteal phase GnRH agonist (n = 90) Placebo (n = 90)
Age (yr) 29.96 ± 3.93 29.73 ± 3.92
Serum estradiol on day 14 after ICSI (pg/mL) 58.12 ± 26.44 96.92 ± 32.8
Serum progesterone on day 14 after ICSI (ng/mL) 21.35 ± 7.18 25.16 ± 13.38
Duration of FSH therapy (d) 10.72 ± 1.90 10.11 ± 2.11
Total amount of FSH given (ampule) 22.9 ± 7.5 22.9 ± 7.7
Oocytes retrieved, n 5.42 ± 2.54 5.89 ± 2.81
Embryos transferred, n 2.25 ± 0.78 2.40 ± 0.79
*Values are mean ± standard deviation; †the differences between the two groups was not significant (p > 0.05). ICSI = intracytoplasmic sperm injection; FSH =
follicle-stimulating hormone.
as the ratio of the number of patients in whom clinical
pregnancy was diagnosed to the total number of patients
who underwent embryo transfer. A p value of ≤ 0.05 was
considered statistically significant.
Results
Infertile couples continued to be assessed until 90
patients were assigned to each of the treatment and
placebo groups.
Patient characteristics were similar between the
treated group and controls. There were no differences
in the concentration of estradiol, progesterone, duration
and dose of hormonal stimulation, number of retrieved
oocytes, and number of embryos transferred (Table 1).
Moreover, no cases of OHSS were found in either the
study or control groups.
An implantation rate of 12.3% was detected in the
GnRH group compared with 7.3% in controls, and the
increase was statistically significant (p =0.042). The clin-
ical pregnancy rate was significantly higher in women
experiencing GnRH administration than in the placebo
group (25.5% vs. 10.0%; p = 0.015; Table 2).
Discussion
The luteal phase is the result of intermittent stimulation
of the corpus luteum by pituitary luteinizing hormone,
and it is different in ART cycles compared with natural
cycles. Luteal phase deficiency is a common feature of
cycles resulting from stimulation of follicular develop-
ment [9] and leads to a decreased embryo implantation
rate, a lower pregnancy rate and an increased miscar-
riage rate when pregnancy is established [2]. The rea-
sons for luteal deficiency are not yet fully understood.
To cope with this problem, luteal phase support can be
provided by hCG or progesterone. According to some
studies, GnRH agonist administration can support the
luteal phase [5–8].
Based on the above observation, we investigated the
effect of GnRH agonist administration in this prospective
randomized study, in a single dose 3 days after embryo
transfer, on luteal phase characteristics and clinical out-
come. Significant differences in implantation and clin-
ical pregnancy rate were found among women with
GnRH administration compared with the control group.
It is in line with the study of Tesarik et al [5] which
showed that mid-luteal GnRH agonist administration
in oocyte donors increased the implantation rate. A
similar study reported that administration of 0.1 mg of
the GnRH agonist triptorelin on day 6 after ICSI led to
a significant improvement in implantation and live birth
rates as compared with placebo [8]. In addition, Pirard
et al [6] administered intranasal buserelin for luteal
phase support and showed that it was associated with
a good pregnancy rate.
Theoretically possible effects of GnRH agonist are
improvements in the function of the endometrium and
corpus luteum and a direct effect on the embryo, or
some combination of these possibilities. In this study,
an improvement in the implantation rate and clinical
pregnancy rate in the GnRH agonist-treated group
appeared not to result from the effect of GnRH ago-
nist on the corpus luteum, because we did not observe
any difference in the serum levels of estradiol and prog-
esterone between the two groups. We also carried out
endometrial support by administering vaginal proges-
terone after embryo transfer which may show a possi-
ble effect of GnRH agonist on the embryo. A direct
effect of the agonist on the endometrium mediated
through locally present GnRH agonist can certainly not
be ruled out. The hypothesis of a direct effect of a
GnRH agonist on the embryo by Tesarik et al [8] has
been suggested by the observation of higher levels of
serum β-hCG in patients who achieved a single preg-
nancy after administration of GnRH agonist compared
with controls. Previous research has shown that GnRH
increased serum hCG in pregnant women [10] by act-
ing on a placental GnRH receptor [11]. However, we
did not observe in our study any differences in serum
β-hCG level among pregnant women in the study
group and controls. The present data showed a posi-
tive effect on pregnancy outcome of single-dose GnRH
agonist administration as luteal phase support. More
information is needed about the possible mechanism of
action of a single dose of agonist as luteal phase sup-
port, and also detailed knowledge has to be gained with
regard to optimal treatment (minimally effective dose
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Table 2. Implantation rate and clinical pregnancy rate in 
gonadotropin-releasing hormone (GnRH) agonist and 
placebo groups
Patient group
Luteal phase Placebo pVariables
GnRH agonist (n = 90)
(n = 90)
Implantation 12.3 7.3 0.042
rate, %
Clinical 23 (25.5) 9 (10.0) 0.015
pregnancy 
rate, n (%)
and timing). Early studies suggested that the GnRH
agonist has a dose-dependent effect on the corpus
luteum. Administration of the GnRH agonist buserelin
at a dose of 500 μg (as used for downregulation in ART
cycles) may act as a luteolytic agent; but in one study, it
was shown that buserelin at lower doses (100 μg) had
a stimulatory effect on the corpus luteum [6].
In the present study, in accordance with the study
of Tesarik et al [8], we did not observe any increase in
the development of OHSS in GnRH agonist-treated
patients. A question may arise about a possible in-
crease in the incidence of OHSS because of a higher
level of hCG by administering luteal phase GnRH ago-
nist, and it may question the safety of GnRH agonist in
high-risk patients. In some animal studies, it has been
shown that administration of GnRH agonist during
the luteal phase not only decreased the expression of
vascular endothelial growth factor receptors, but also
might prevent OHSS [12]. Therefore, it seems that luteal
phase support by GnRH agonist does not have any
adverse effect, but caution is recommended until more
details on the effect of luteal phase GnRH agonist
administration are available.
The results of this study showed a beneficial effect
of GnRH agonist administration as luteal phase support
on pregnancy outcomes in ART as in previous studies,
but more studies investigating the optimal dose and
exact mechanism of the beneficial effect of a GnRH
agonist are needed.
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